Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-138995
Abstract: Background and Objective 15% of pediatric and 40% of adult T-cell Acute Lymphoblastic Leukemia (T-ALL) patients fail conventional therapy highlighting the need for novel therapeutic strategies based on genomic alterations of individuals. We interrogated genomic… read more here.
Keywords: generation genomic; genomic abnormalities; cdkn2a deletions; deletion ... See more keywords
Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13205055
Abstract: Simple Summary AML is a heterogenous malignancy with a variety of underlying genomic abnormalities. Some of the genetic aberrations in AML have led to the development of specific inhibitors which were approved by the Food… read more here.
Keywords: genomic abnormalities; medicine; myeloid leukemia; therapeutic targets ... See more keywords
Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23042362
Abstract: We describe recent updates of existing molecular-targeting agents and emerging novel gene-specific strategies. FLT3 and IDH inhibitors are being tested in combination with conventional chemotherapy for both medically fit patients and patients who are ineligible… read more here.
Keywords: emerging targeted; therapy; genomic abnormalities; targeted therapy ... See more keywords